Side-by-side · Research reference

IGF-DESvsSNAP-8

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED8/60 cited

BHuman-MechanisticHUMAN-REVIEWED8/46 cited

IGF-DES

IGF-1 Analogue · Truncated N-Terminal

~10×Potency vs IGF-1

ReducedIGFBP binding

ResearchStatus

Injection (local or systemic) · Research protocols onlyBredehöft 2008

SNAP-8

Synthetic Octapeptide · Cosmetic Topical

TopicalRoute

8-AAPeptide length

SNAREPrimary target

Topical · Facial application · Twice daily

01Mechanism of Action

Parameter

IGF-DES

SNAP-8

Primary target

IGF-1 receptor (IGF1R)Shields 2007

SNARE complex (SNAP-25 competitive binding site)

Pathway

IGF1R activation → PI3K/Akt & MAPK signaling → protein synthesis, proliferation

Acetyl octapeptide-3 → SNARE complex disruption → Reduced vesicular fusion → Decreased acetylcholine release → Muscle relaxation

Downstream effect

Enhanced muscle protein synthesis, myoblast differentiation, reduced apoptosis, cell proliferation

Transient reduction in neuromuscular signal transmission, decreased muscle contraction amplitude, wrinkle depth reduction

Feedback intact?

Unknown — no human endocrine feedback data

N/A — topical cosmetic, no systemic endocrine axis

Origin

Synthetic truncation of native IGF-1 — removal of N-terminal Gly-Pro-Glu tripeptideBredehöft 2008

Synthetic peptide derived from N-terminal fragment of SNAP-25 protein (synaptosomal-associated protein 25 kDa)

Antibody development

—

02Dosage Protocols

Parameter

IGF-DES

SNAP-8

Research dose range

10–100 ng/mL (in vitro); μg doses (animal models)

Highly context-dependent; no standardized human protocol.

—

Route

Subcutaneous or intramuscular (local injection favored)

Local delivery maximizes tissue-specific uptake.

—

Frequency

Variable — daily to multiple times daily in research

—

Evidence basis

Animal models + in vitro only

RCT, in vitro skin penetration studies

Human data

None — no clinical trials

—

Half-life

Shorter than IGF-1 due to reduced IGFBP binding

Rapid tissue uptake, limited systemic circulation.

—

Typical concentration

—

2–10% in cosmetic formulationsLupin 2024 Raikou 2017

Commercial products typically use 5–10%.

Application frequency

—

Twice daily (morning and evening)Lupin 2024

Treatment duration

—

20–60 days for visible effectRaikou 2017

Skin microtopography improvements measured at 20-day intervals.

Formulation type

—

Oil-in-water emulsion, serum, cream

Application site

—

Facial skin — glabellar lines, crow's feet, forehead

Onset of effect

—

Visible reduction in wrinkle depth by day 20–28Raikou 2017

03Metabolic / Fat Loss Evidence

Parameter

IGF-DES

SNAP-8

Primary mechanism

Indirect via muscle hypertrophy → metabolic rate elevation

—

Direct lipolysis

Minimal evidence — IGF-1 axis primarily anabolic, not lipolytic

—

Prostate model

Inhibited BPH cell proliferation when combined with vitamin D3 analogueCrescioli 2002

Context-specific anti-proliferative effect, not fat loss.

—

04Side Effects & Safety

Parameter

IGF-DES

SNAP-8

Hypoglycemia risk

Theoretical — IGF-1 axis enhances glucose uptake

—

Mitogenic risk

Chronic IGF-1 receptor activation may promote cell proliferation, potential tumor growthCrescioli 2002

—

Injection site reaction

Expected — erythema, irritation, local swelling

—

Edema / Fluid retention

Possible via sodium retention (IGF-1 axis effect)

—

Human safety data

Absent — no human trials, all effects theoretical or extrapolated

—

Unknown long-term effects

No chronic dosing studies in humans; endocrine, metabolic consequences unknown

—

Cytotoxicity

—

Concentration-dependent antiproliferative effect observed in vitro; IC50 ~10 mg/mL (argireline, 6-AA analogue)

Commercial formulations typically use 0.05–0.1 mg/mL, well below cytotoxic threshold.

Skin irritation

—

Minimal; well-tolerated in clinical use

Peptide oxidation

—

Methionine residue susceptible to oxidation in formulation; may reduce efficacyKluczyk 2021

Formulation stability issue, not a direct adverse effect.

Systemic absorption

—

Negligible; peptide remains in stratum corneum and epidermisKraeling 2015

Hypersensitivity

—

Rare; no widespread allergic reactions reported

Absolute Contraindications

IGF-DES

·Active malignancy or history of cancer (mitogenic risk)
·Pregnancy / lactation (no safety data)
·Hypoglycemia disorders

SNAP-8

·Known hypersensitivity to acetyl octapeptide-3 or formulation excipients

Relative Contraindications

IGF-DES

·Diabetes mellitus (unpredictable glucose effects)
·Renal or hepatic impairment (clearance unknown)
·Edema-prone conditions (heart failure, nephrotic syndrome)

SNAP-8

·Active skin infections or open wounds at application site
·Neuromuscular disorders (theoretical concern, no documented cases)

05Administration Protocol

Parameter

IGF-DES

SNAP-8

1. Research context only

Des(1-3)IGF-1 has no approved human protocol. All administration details are derived from animal or in vitro research and should not be construed as medical guidance.

Wash face with gentle cleanser and pat dry. Remove makeup and surface oils to optimize peptide contact.

2. Reconstitution (if lyophilized)

Sterile water or bacteriostatic water per research protocol. Gently swirl; do not shake. Store reconstituted peptide at 2–8 °C.

Apply 1–2 drops or pea-sized amount of SNAP-8 serum or cream to target areas (forehead, glabellar lines, crow's feet). Gently massage until absorbed.

3. Injection site

Subcutaneous (abdomen, thigh) or intramuscular (deltoid, vastus lateralis). Local injection to target tissue (e.g., muscle group) may enhance regional uptake.

Twice daily — morning and evening. Allow 2–3 minutes for absorption before applying additional skincare products.

4. Timing

Frequency and timing vary by research design. Post-exercise or fasted state may theoretically enhance muscle uptake.

Apply before heavier creams or occlusive moisturizers. Peptides penetrate best from water-based serums on clean skin.

5. Needle gauge

27–31G insulin syringe for subcutaneous; 25–27G for intramuscular.

Store at room temperature, away from direct sunlight. Refrigeration may extend shelf life of formulations containing unstable peptides.

6. Monitoring

Glucose monitoring essential (hypoglycemia risk). No established IGF-1 or safety labs for human use.

Consistent use for 20–60 days required for visible wrinkle reduction. Effects are temporary and reverse upon discontinuation.

06Stack Synergy

IGF-DES

+ BPC-157

Moderate

View BPC-157 →

Des(1-3)IGF-1 promotes myoblast differentiation and protein synthesis, while BPC-157 enhances tissue repair, angiogenesis, and collagen synthesis. Both act on distinct pathways (IGF1R vs gastric pentadecapeptide mechanisms) to support muscle recovery and connective tissue integrity. Synergy is mechanistic but lacks direct co-administration studies.

Des(1-3)IGF-1: Research dose post-workout (local IM)
BPC-157: 250–500 mcg SQ, daily or twice daily
Frequency: Daily or per research protocol
Primary benefit: Accelerated muscle repair, enhanced hypertrophy, connective tissue support

+ TB-500

Moderate

View TB-500 →

TB-500 (Thymosin Beta-4 fragment) promotes cell migration, angiogenesis, and wound healing via actin regulation. Des(1-3)IGF-1 drives protein synthesis and myoblast proliferation. Combined, these peptides may synergistically enhance muscle recovery, repair, and hypertrophy through complementary anabolic and regenerative pathways. No direct human co-administration data.

Des(1-3)IGF-1: Research dose post-workout (local IM)
TB-500: 2–5 mg SQ, 2× weekly
Frequency: Per research cycle
Primary benefit: Muscle hypertrophy, injury recovery, vascular support

SNAP-8

— no documented stacks